FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283713497> ?p ?o ?g. }

• W4283713497 endingPage "2100" @default.
• W4283713497 startingPage "2087" @default.
• W4283713497 abstract "Clinical trials study treatment outcomes under stringent conditions, capturing incompletely the heterogeneity of patient populations and treatment complexities encountered in real-world practice.To compare the effectiveness of anti-interleukin (IL)-17A biologics relative to other approved biologics in patients with moderate-to-severe psoriasis.The Psoriasis Study of Health Outcomes (PSoHO) is an ongoing 3-year observational cohort study in adults with chronic moderate-to-severe plaque psoriasis initiating or switching to a new biologic. Primary study endpoint is the proportion of patients achieving 90% improvement in Psoriasis Area and Severity Index (PASI 90) and/or static Physician Global Assessment (sPGA) 0/1 at Week 12 (W12) in the anti-IL-17A cohort (ixekizumab [IXE], secukinumab) vs. all other approved biologics. Secondary outcomes include the proportion of patients who achieve PASI 75/90/100, absolute PASI scores ≤5, ≤2 and ≤1, Dermatology Life Quality Index (DLQI) score of 0/1 at W12 between the two cohorts and among the individual biologics. Comparative effectiveness analyses were conducted using Frequentist Model Averaging (FMA), a novel causal inference machine learning approach. Missing data for binary outcomes were imputed as non-response.Patient profiles in the anti-IL-17A cohort and other biologics cohort were similar, with more frequent comorbid psoriatic arthritis and less frequent exposure to conventional treatments in the patients receiving anti-IL-17A biologics. At W12, 71.4% of patients who received an anti-IL-17A biologic achieved PASI 90 and/or sPGA 0/1 compared to 58.6% of patients who received other biologics (odds ratios [OR], 1.9; 95% confidence intervals [CI], [1.6, 2.4]). Similar findings were observed for secondary outcomes.These results reflect the high efficacy and early onset of skin clearance of IL-17A inhibitors observed in randomized clinical trials and confirm the effectiveness of anti-IL-17A biologics in the real-world setting." @default.
• W4283713497 created "2022-06-30" @default.
• W4283713497 creator A5012738162 @default.
• W4283713497 creator A5020129995 @default.
• W4283713497 creator A5021906179 @default.
• W4283713497 creator A5027590834 @default.
• W4283713497 creator A5038515214 @default.
• W4283713497 creator A5038781275 @default.
• W4283713497 creator A5040210846 @default.
• W4283713497 creator A5042776890 @default.
• W4283713497 creator A5043735914 @default.
• W4283713497 creator A5051742131 @default.
• W4283713497 creator A5053176930 @default.
• W4283713497 creator A5062276217 @default.
• W4283713497 creator A5063264985 @default.
• W4283713497 creator A5075524952 @default.
• W4283713497 creator A5082049025 @default.
• W4283713497 date "2022-07-29" @default.
• W4283713497 modified "2023-10-16" @default.
• W4283713497 title "Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational <i>psoriasis study of health outcomes</i> (<scp>PSoHO</scp>)" @default.
• W4283713497 cites W1881545913 @default.
• W4283713497 cites W1985951317 @default.
• W4283713497 cites W2045676810 @default.
• W4283713497 cites W2054723033 @default.
• W4283713497 cites W2097896724 @default.
• W4283713497 cites W2217326824 @default.
• W4283713497 cites W2346401928 @default.
• W4283713497 cites W2583701315 @default.
• W4283713497 cites W2597329772 @default.
• W4283713497 cites W2735301415 @default.
• W4283713497 cites W2768998510 @default.
• W4283713497 cites W2783964106 @default.
• W4283713497 cites W2902141660 @default.
• W4283713497 cites W2912058252 @default.
• W4283713497 cites W2930875443 @default.
• W4283713497 cites W2967003334 @default.
• W4283713497 cites W2967437723 @default.
• W4283713497 cites W2988575006 @default.
• W4283713497 cites W3017227908 @default.
• W4283713497 cites W3036523869 @default.
• W4283713497 cites W3107342060 @default.
• W4283713497 cites W3121863281 @default.
• W4283713497 cites W3126106680 @default.
• W4283713497 cites W3143775625 @default.
• W4283713497 cites W3149331822 @default.
• W4283713497 cites W3157494418 @default.
• W4283713497 cites W3196360680 @default.
• W4283713497 cites W3211379308 @default.
• W4283713497 cites W4214694007 @default.
• W4283713497 doi "https://doi.org/10.1111/jdv.18376" @default.
• W4283713497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35766124" @default.
• W4283713497 hasPublicationYear "2022" @default.
• W4283713497 type Work @default.
• W4283713497 citedByCount "9" @default.
• W4283713497 countsByYear W42837134972022 @default.
• W4283713497 countsByYear W42837134972023 @default.
• W4283713497 crossrefType "journal-article" @default.
• W4283713497 hasAuthorship W4283713497A5012738162 @default.
• W4283713497 hasAuthorship W4283713497A5020129995 @default.
• W4283713497 hasAuthorship W4283713497A5021906179 @default.
• W4283713497 hasAuthorship W4283713497A5027590834 @default.
• W4283713497 hasAuthorship W4283713497A5038515214 @default.
• W4283713497 hasAuthorship W4283713497A5038781275 @default.
• W4283713497 hasAuthorship W4283713497A5040210846 @default.
• W4283713497 hasAuthorship W4283713497A5042776890 @default.
• W4283713497 hasAuthorship W4283713497A5043735914 @default.
• W4283713497 hasAuthorship W4283713497A5051742131 @default.
• W4283713497 hasAuthorship W4283713497A5053176930 @default.
• W4283713497 hasAuthorship W4283713497A5062276217 @default.
• W4283713497 hasAuthorship W4283713497A5063264985 @default.
• W4283713497 hasAuthorship W4283713497A5075524952 @default.
• W4283713497 hasAuthorship W4283713497A5082049025 @default.
• W4283713497 hasBestOaLocation W42837134971 @default.
• W4283713497 hasConcept C126322002 @default.
• W4283713497 hasConcept C16005928 @default.
• W4283713497 hasConcept C1862650 @default.
• W4283713497 hasConcept C201903717 @default.
• W4283713497 hasConcept C203092338 @default.
• W4283713497 hasConcept C23131810 @default.
• W4283713497 hasConcept C2776173921 @default.
• W4283713497 hasConcept C2776260265 @default.
• W4283713497 hasConcept C2777011040 @default.
• W4283713497 hasConcept C2778975655 @default.
• W4283713497 hasConcept C2779134260 @default.
• W4283713497 hasConcept C2779745271 @default.
• W4283713497 hasConcept C2779786854 @default.
• W4283713497 hasConcept C2780132546 @default.
• W4283713497 hasConcept C2780564577 @default.
• W4283713497 hasConcept C535046627 @default.
• W4283713497 hasConcept C71924100 @default.
• W4283713497 hasConcept C72563966 @default.
• W4283713497 hasConceptScore W4283713497C126322002 @default.
• W4283713497 hasConceptScore W4283713497C16005928 @default.
• W4283713497 hasConceptScore W4283713497C1862650 @default.
• W4283713497 hasConceptScore W4283713497C201903717 @default.
• W4283713497 hasConceptScore W4283713497C203092338 @default.
• W4283713497 hasConceptScore W4283713497C23131810 @default.
• W4283713497 hasConceptScore W4283713497C2776173921 @default.

• next